Fig. 4From: Pre-treatment metastatic growth rate is associated with clinical outcome in patients with metastatic renal cell carcinoma treated with nivolumabScatter plots of responders (complete response, partial response, or stable disease (SD) for ≥ 6 months (long SD)) and non-responders (stable disease (SD) for < 6 months (short SD) or Progressive Disease). The median MGR was significantly lower in responders (p = 0.02)Back to article page